A frequent question in the clinic is “What’s new in Parkinson’s?”  It is a deceptively simple question, because the truth is that there are thousands of researchers around the world working on Parkinson disease (PD), and there is no way to answer the question in anything close to the time of a follow-up appointment in … Continue reading Pipeline drugs, part 1: levodopa